Form 4: Aprea Therapeutics Director Jean-Pierre Bizzari Receives Equity Compensation

Aprea Therapeutics, Inc. Director Jean-Pierre Bizzari was granted 1,045 restricted stock units and options to purchase 4,185 shares of common stock on June 5, 2025, as part of his compensation.

Summary

• Jean-Pierre Bizzari, a Director of Aprea Therapeutics, Inc. (APRE), acquired new equity compensation on June 5, 2025.
• The acquisition includes 1,045 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.00 per share.
• Additionally, he was granted stock options to purchase 4,185 shares of common stock at an exercise price of $1.81 per share.
• Both the RSUs and stock options are scheduled to vest in full on June 5, 2026, contingent on his continued service on the board.
• The stock options have an expiration date of June 5, 2035.
• Following these transactions, Mr. Bizzari beneficially owns 1,045 shares of common stock and 4,185 stock options directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a positive sign of continued alignment and commitment, but does not contain information that would significantly alter the company's fundamental outlook.

Positives

• Director Jean-Pierre Bizzari received equity compensation, aligning his interests with shareholders.
• The grants include both restricted stock units and stock options, providing a mix of immediate and long-term incentives.
• The vesting schedule encourages continued service on the board of directors.

Risks

• The vesting of the restricted stock units and stock options is subject to the reporting person's continued service on the Issuer's board of directors.
• The value of the stock options is dependent on the future stock price exceeding the exercise price of $1.81.

Future Outlook

The document indicates future vesting of equity compensation for a director, contingent on continued service, suggesting an expectation of ongoing board involvement.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract and retain experienced directors and executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) and stock options to a director is a common form of non-cash compensation in the biotech sector, comparable to practices at companies like BioNTech or Moderna, which frequently use equity to incentivize leadership.
• The vesting schedule, typically over one year for director grants, is consistent with industry benchmarks for board compensation, ensuring continued commitment.
• The exercise price of $1.81 for the options is based on the market price at the time of grant, a standard practice to ensure options are 'at-the-money' upon issuance.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, as the value of his compensation is tied to the company's stock performance.

Next Steps

• The restricted stock units and stock options are expected to vest on June 5, 2026, subject to the director's continued service.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Jean-Pierre Bizzari, SEC Filing